Generate Biomedicines (GENB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.52
- Estimate
- -$0.49
- Surprise
- -6.1%
- Revenue (period 2026-06-30)
- $6.3M
- Score today
- 4.7/10
Revenue source: xbrl.
How the report landed
Generate Biomedicines (GENB) reported a wider loss than forecast — adjusted EPS of -$0.52 against the -$0.49 estimate (a 6.1% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates GENB Sell at 4.7/10; no pre/post engine snapshot brackets this report.
0 of the last 2 quarters beat the estimate; this quarter's -6.1% surprise compares with a -58.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (2.8 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 6.0), Material insider selling (6 sells, 4.87% of cap)
- EARNINGS_PROXIMITY:6d<=7d
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $15.38
- Price target
- $23.49
- Stop
- $14.30
- Upside to target
- +52.7%
- Reward-to-risk
- 3.5:1
Risk check: trading volume is running 3.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
GENB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.97B
- P/E (fwd)
- -6.7
- 52-week range
- $11.00–$22.67
- Off 52-week high
- 32.2%
- RSI (14)
- 58
- Volume vs avg
- 3.75×
- Score today
- 4.7/10